Sumitomo Life Insurance Co. Acquires 8,299 Shares of Iqvia Holdings Inc (NYSE:IQV)

Sumitomo Life Insurance Co. increased its holdings in Iqvia Holdings Inc (NYSE:IQV) by 95.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,981 shares of the medical research company’s stock after purchasing an additional 8,299 shares during the quarter. Sumitomo Life Insurance Co.’s holdings in Iqvia were worth $2,624,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of IQV. Usca Ria LLC bought a new stake in shares of Iqvia in the third quarter worth about $29,000. Patriot Financial Group Insurance Agency LLC grew its stake in shares of Iqvia by 379.5% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 211 shares of the medical research company’s stock worth $33,000 after purchasing an additional 167 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in shares of Iqvia in the third quarter worth about $38,000. Massey Quick Simon & CO. LLC bought a new stake in shares of Iqvia in the third quarter worth about $43,000. Finally, Lenox Wealth Management Inc. bought a new stake in shares of Iqvia in the third quarter worth about $51,000. 89.76% of the stock is currently owned by institutional investors.

In other news, Director Michael J. Evanisko sold 6,250 shares of Iqvia stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $160.76, for a total transaction of $1,004,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Michael R. Mcdonnell sold 12,000 shares of Iqvia stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the transaction, the chief financial officer now owns 14,366 shares of the company’s stock, valued at $2,227,735.62. The disclosure for this sale can be found here. Insiders have sold 24,500 shares of company stock valued at $3,866,090 over the last quarter. Company insiders own 6.00% of the company’s stock.

Several research firms recently issued reports on IQV. Cfra raised Iqvia from a “sell” rating to a “hold” rating in a research note on Friday, December 13th. Wolfe Research raised Iqvia from a “peer perform” rating to an “outperform” rating in a research note on Thursday, November 14th. ValuEngine cut Iqvia from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Citigroup assumed coverage on Iqvia in a research note on Monday, January 6th. They issued a “buy” rating and a $185.00 target price on the stock. Finally, Wells Fargo & Co assumed coverage on Iqvia in a research report on Tuesday, January 7th. They set an “overweight” rating and a $180.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $169.10.

Iqvia stock traded down $3.65 during trading hours on Friday, hitting $158.14. 38,800 shares of the stock traded hands, compared to its average volume of 971,294. The firm’s 50-day moving average price is $154.00 and its two-hundred day moving average price is $151.64. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 1.85. The company has a market cap of $31.14 billion, a PE ratio of 129.75, a PEG ratio of 1.70 and a beta of 0.88. Iqvia Holdings Inc has a one year low of $123.57 and a one year high of $164.13.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $1.60 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.57 by $0.03. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.76 billion. During the same period in the previous year, the firm posted $1.42 EPS. The business’s revenue was up 6.7% on a year-over-year basis. On average, sell-side analysts expect that Iqvia Holdings Inc will post 5.9 earnings per share for the current fiscal year.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading: What is the quiet period?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit